Development of Point of Care (POC) for creatinine with electrochemical biosensor

• Grant number: 22/15715-4
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Duration: April 01, 2023 - September 30, 2025
• Field of knowledge: Physical Sciences and Mathematics - Chemistry - Analytical Chemistry
• Principal Investigator: Déborah Christine Azzi
• Grantee: Déborah Christine Azzi
• Host Company: ADB Pesquisa e Desenvolvimento Ltda
• CNAE: Pesquisa e desenvolvimento experimental em ciências físicas e naturais
• City: Araras
• Associated researchers: Bruno Campos Janegitz
• Associated research grant: 20/13799-0 - Development of Point of Care (POC) for creatinine with electrochemical biosensor, AP.PIPE
• Associated scholarship(s): 24/04258-7 - Development of "Point of Care" (POC) for creatinine with electrochemical biosensor., BP.TT; 23/06654-4 - Development of "Point of Care" (POC) for creatinine with electrochemical biosensor., BP.TT; 23/06421-0 - Development of "Point of Care" (POC) for creatinine with electrochemical biosensor., BP.TT; 23/06857-2 - Development of "Point of Care" (POC) for creatinine with electrochemical biosensor., BP.TT; 23/05759-7 - Development of Point of Care (POC) for creatinine with electrochemical biosensor, BP.PIPE

Abstract

Chronic Kidney Disease (CKD) is a condition that is silent and asymptomatic in the early stages and is characterized by a gradual loss of kidney function over time. It can be caused by diabetes, high blood pressure, high cholesterol, etc. The number of cases has been increasing in the last decades, putting the health system under immense pressure, and worrying world authorities. Around 850 million people in the world and 17 million in Brazil are affected by the disease at some stage. It is projected to become the 5th most common cause of years of life lost globally by 2040. In 2015, the number of deaths hit 1.2 million people worldwide, 35 thousand in Brazil in 2017. An early diagnosis can slow or stop the progression of kidney disease. Creatinine is the biological marker with the highest clinical relevance for CKD, it can be found in human blood and urine, filtered by the kidneys at a constant rate. Creatinine is a breakdown product of creatine and phosphocreatine, which are involved in the energy metabolism of skeletal muscle. Changes in blood or urine creatinine levels indicate the kidneys and muscular functions, besides indicating thyroid dysfunction. The world's lack of portable diagnostic devices for Point of care testing for creatinine and the increase in the demand for rapid tests indicate an excellent commercial opportunity. Thus, our main goal is to develop point-of-care portable diagnostic devices based on electrochemical biosensors for determining the concentration of creatinine in human serum or urine, making it possible to calculate the estimated glomerular filtration rate (eGFR), which indicates kidney function. The main advantages, when compared to conventional analysis colorimetric techniques, are the low operational cost, time of analysis, complexity, and sample quantity, making it possible to perform the exam at drugstores, doctor's offices and infirmaries, without any qualified person, needed. Besides, due to the fact it is portable and low cost, the device will be able to be transported and used for mass testing in rural communities and remote villages. (AU)